Mateon Therapeutics

San Francisco, United States Founded: 1996 • Age: 30 yrs Listed
Vascular targeted therapies are developed for rare diseases and cancers.

About Mateon Therapeutics

Mateon Therapeutics is a publicly listed company based in San Francisco (United States) founded in 1996. Vascular targeted therapies are developed for rare diseases and cancers. Mateon Therapeutics has completed 2 acquisitions, including PointR Data and Symphony Vida. Mateon Therapeutics offers products and services including OT-101, CA4P, and OXi4503. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Mateon Therapeutics, Inc. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.

Company details

Mateon Therapeutics is a developer of vascular targeted therapy for the treatment of rare diseases cancers. It is developing vascular targeted therapy (VTT) including vascular disrupting agents (VDAs) anti-angiogenic agents (AAs) for the treatment of rare cancers. Its drug pipeline CA4P (VDA) is being developed in combination with bevacizumab chemotherapy for platinum-resistant ovarian cancer (prOC) (Phase 23) with pazopanib for the treatment of recurrent ovarian cancer (Phase 1b2)with bevacizumab for glioblastoma multiforme (Phase 23). It has developed OXi4503 (VDA) in combination with cytarabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

  • Headquarters San Francisco, United States
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website mateon.com
  • Social LinkedIn X YouTube
  • Legal Name Mateon Therapeutics, Inc.
Operational Areas
Key Metrics

Products & Services of Mateon Therapeutics

Mateon Therapeutics offers a comprehensive portfolio of products and services, including OT-101, CA4P, and OXi4503.

OT-101
RNA Therapeutic

Anti-TGF-β drug for cancer and infectious disease treatment.

CA4P
Small Molecule Drug

Targets melanoma in rare pediatric cancers.

OXi4503
Small Molecule Drug

Treats acute myeloid leukemia in pediatric cases.

Apps and channels of Mateon Therapeutics

its YouTube channel ONCOTELIC THERAPEUTICS has 87 subscribers and 19 videos.

ONCOTELIC THERAPEUTICS
YouTube 87 subscribers 19 videos Science & Technology
Open channel

Videos from Mateon Therapeutics

The most watched videos on Mateon Therapeutics's YouTube channel, ONCOTELIC THERAPEUTICS (87 subscribers). Click a video to play it here.

Dr. Triue, the CEO, was interviewed on Benzinga All Access on November 8, 2023.
1.9K views
Oncotelic; Announcing Successful Joint Venture and Diving into Benefits for Shareholders
1.9K views
Oncotelic; Diving into the Company's Outlook for 2022
1.7K views
Oncotelic; An Introduction to Chief Clinical Officer Anthony Maida & His Background
1.5K views

More on ONCOTELIC THERAPEUTICS.

Funding Insights of Mateon Therapeutics

  • Total Rounds 7
  • Last Round Post-IPO β€” $600,000
  • First Round $15M

    (Jul 2003)

  • Investors Count 1

All 7 funding rounds of Mateon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2019$600,000Post-IPO––
–
Apr 2018$2.93MPost-IPO––
–
Apr 2013$5MPost-IPO––
–
Nov 2010$733,000Grant––
Mar 2010$7.5MPost-IPO––
–
Mar 2010$7.5MPost-IPO––
–
Jul 2003$15MPost-IPO––
–
Valuation history

1 investors in total: 1 institutional.

Investors in Mateon Therapeutics

Mateon Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Internal Revenue Service.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Tax administration and collection services by the US government.
irs.gov
Premium access

Investor details for Mateon Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Mateon Therapeutics

Mateon Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include PointR Data and Symphony Vida.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Edge AI computing solutions for drones and robotics are provided.
pointr.aiSan Jose, United States2018Nov 2019β€’β€’β€’β€’
Therapeutics for cancer and eye diseases are developed.
symphonyvida.comRockville, United States0Jul 2009$12.5M
Premium access

Complete acquisition details for Mateon Therapeutics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Mateon Therapeutics

6 dated milestones of Mateon Therapeutics across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded Mateon Therapeutics is founded.
  2. Funding First funding round of $15.0M.
  3. Acquisition Acquires Symphony Vida.
  4. IPO Lists on the stock exchange (IPO).
  5. Funding Latest funding round, Post-IPO, of $600K.
  6. Acquisition Acquires PointR Data.

Competitors of Mateon Therapeutics

Mateon Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
c4therapeutics.com2016Cambridge, United States$223M121
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
erasca.com2018San Diego, United States$300M120
Small molecule therapeutics for cancer treatment are developed.
revmed.com2014Redwood, United States$326.29M181
Cancer therapies are developed using selective pathway inhibitors.
Premium access

Detailed competitors of Mateon Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Mateon Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Mateon Therapeutics

Premium access

Complete news archive for Mateon Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Mateon Therapeutics

Mateon Therapeutics was founded in 1996 and raised its 1st funding round 7 years after it was founded.

Mateon Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Mateon Therapeutics is a developer of vascular targeted therapy for the treatment of rare diseases cancers. It is developing vascular targeted therapy (VTT) including vascular disrupting agents (VDAs) anti-angiogenic agents (AAs) for the treatment of rare cancers. Its drug pipeline CA4P (VDA) is being developed in combination with bevacizumab chemotherapy for platinum-resistant ovarian cancer (prOC) (Phase 23) with pazopanib for the treatment of recurrent ovarian cancer (Phase 1b2)with bevacizumab for glioblastoma multiforme (Phase 23). It has developed OXi4503 (VDA) in combination with cytarabine for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Mateon Therapeutics's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.

Mateon Therapeutics offers OT-101, CA4P, and OXi4503.

Mateon Therapeutics has made 2 acquisitions, including PointR Data, and Symphony Vida.

Mateon Therapeutics has 1 investor. Key investors include Internal Revenue Service.

Mateon Therapeutics operates through Mateon Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available